CLDX

Celldex Therapeutics, Inc.

CLDX · CIK 744218 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$2M
20182025
Net Income−$259M
20182025
Operating CF−$211M
20182025
Free Cash Flow−$214M
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Cost of Revenue$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Gross Profit————————
R&D Expense$0.2B$0.2B$0.1B$0.1B$0.1B$0.0B$0.0B$0.1B
SG&A Expense————————
Operating Income$-0.3B$-0.2B$-0.2B$-0.1B$-0.1B$-0.1B$-0.1B$-0.2B
Net Income$-0.3B———————
EPS (Basic)$-3.90$-2.45$-2.92$-2.40$-1.64———
EPS (Diluted)$-3.90$-2.45$-2.92$-2.40$-1.64———

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.6B$0.8B$0.5B$0.4B$0.4B$0.2B$0.1B$0.2B
Current Assets$0.5B$0.7B$0.4B$0.3B$0.4B$0.2B$0.1B$0.1B
Cash & Equivalents$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Total Liabilities$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.5B$0.7B$0.4B$0.3B$0.4B$0.2B$0.1B$0.1B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.2B$-0.2B$-0.1B$-0.1B$-0.1B$-0.0B$-0.0B$-0.1B
Investing Cash Flow$0.2B$-0.3B$-0.1B$0.1B$-0.2B$-0.1B$0.0B$0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.0B$0.4B$0.2B$0.0B$0.3B$0.2B$0.0B$0.0B
← Companies